52 results about "Transmembrane protein" patented technology

The invention belongs to the technical field of medical chemistry, and particularly relates to a targeted protein degradation compound containing an SYVN1 binding compound and application of the targeted protein degradation compound. According to the invention, a series of compounds interacting with SYVN1 are found, and the compounds can be used as'warheads' to participate in ERAD and effectively degrade transmembrane protein targets. Based on the SYVN1 binding compound, a new TPD technology for hijacking ERAD is established, and a brand new platform is provided for processing TMSPs and other proteins which are difficult to target by the current TPD technology. A SYVN1 interaction compound is further connected with a known ligand interacting with a protein target through a chemical linker, a series of ERADEC molecules are generated, the molecules can significantly degrade target protein, and a new possibility is provided for targeted degradation of drugs.

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

The present application relates to the field of biotechnology, in particular to a kit based on functionalized magnetic beads and application thereof in the field of stem cells. The functionalized magnetic beads of the present application are loaded with extracellular matrix proteins on the surface, and the extracellular matrix proteins are selected from collagen. The functionalized magnetic beads of the present application realize efficient capture and enrichment of collagen-bound transmembrane proteins, combined with mass spectrometry identification, and are suitable for screening stem cell transmembrane proteins, studying the action sites of stem cells and matrix, or developing drugs targeting stem cells. The kit and method of the present application have the technical advantages of simple operation, good stability and strong specificity, and provide a powerful tool for systematic study of the cell-matrix interaction mechanism mediated by stem cell transmembrane proteins.

Methods and compositions for treating a corneal wound and / or increasing a population of limbal epithelial stem cells (LESCs) and / or early transit amplifying cells (eTAs) in the limbal epithelium of a subject in need thereof. The methods can include administering a therapeutic agent to the subject that: i) results in an increase in concentration of IFITM1 (Interferon Induced transmembrane Protein 1) in the limbal epithelium of the subject; and / or ii) results in a decrease in concentration of OVOL1 (Ovo Like Zinc Finger 1) in the limbal epithelium of the subject. Also provided are adeno-associated viruses (AAVs). The AAVs comprise a heterologous nucleic acid sequence encoding IFITM1 or a variant thereof, operably linked to a regulatory sequence.

The application discloses a kind of bionic transmembrane protein affinity chromatography column and its preparation method and application.The system (iSTAC) realizes the in-situ construction of transmembrane protein in highly bionic dynamic microenvironment by integrating cell-free protein synthesis, functional mesoporous silica modification and amphiphilic (AH) peptide stabilized planar lipid bilayer technology.The core is to use long-chain PEG-24 crosslinking agent to retain lipid bilayer on the surface of silica gel, provide sufficient conformational dynamic space for multi-transmembrane protein, and introduce AH peptide to repair membrane defects, ensure that the receptor realizes directional embedding while maintaining natural functional attributes.The preparation cycle is shortened from 168 hours to 5 hours, which significantly improves the efficiency of targeted drug screening and in-situ analysis of binding sites.Using this platform, 5-HT 1A Receptor agonists crocin I and crocin II with anti-insomnia and neuroprotective effects are successfully screened from saffron, and the action site is accurately depicted.

The application discloses an exosome drug delivery system with anti-phagocytosis and tumor targeting ability as well as a preparation method and application thereof. A tumor targeting group is flexibly connected to the outside of the cell membrane of a transmembrane protein with anti-phagocytosis ability through a linker of a fusion protein. A fusion gene sequence is designed and inserted into an expression vector to form a fusion expression vector, which is integrated into the chromosome of a cell to be modified to obtain an engineered cell stably expressing the fusion protein, which is used for secreting engineered exosomes. The cell to be modified includes a naked cell (an immortalized cell line, a primary cell), an engineered cell stably expressing a therapeutic nucleic acid molecule or a protein. The exosomes produced by the former cell can further package the therapeutic molecules to treat tumors, and the exosomes produced by the latter cell can be directly used for treating tumors after being separated, purified and collected. The half-life of the engineered exosomes produced by the application is significantly prolonged in the body, the treatment effect is improved, and the exosomes show strong tumor targeting and anti-tumor effects in vivo and in vitro.

The application provides a screening method of human amniotic membrane mesenchymal stem cells (hAMSCs) with bone regeneration promoting potential, and uses the protein level of transmembrane protein 119 (TMEM119) as a functional index of the bone regeneration promoting ability of the hAMSCs, and uses an enzyme-linked immunosorbent assay (ELISA) to detect the TMEM119 protein concentration in a lysis solution prepared from 1×10 7 The application uses the TMEM119 protein concentration not lower than 15000 pg / mL as a screening standard of the hAMSCs with bone regeneration promoting potential, and screens the hAMSCs with significant bone regeneration promoting potential from different batches of hAMSCs, so that the hAMSCs meeting the screening standard of the application have obvious bone formation promoting potential, and the technical problem that the hAMSCs with bone regeneration promoting potential are difficult to be accurately identified and screened in clinical transformation is solved.

The invention discloses a preparation method of a nano-enzyme preparation as well as a product and application of the nano-enzyme preparation. The synthesis method of the nano-enzyme preparation comprises the following steps: mixing a transmembrane protein solution and a solution containing one or more nano-enzymes to prepare the nano-enzyme preparation. The nano-enzyme can target a disease site, and on one hand, the nano-enzyme removes active oxygen and active nitrogen species on the disease site; on the other hand, the nano-enzyme can be combined with cytokines of disease parts, the promotion effect of the cytokines on diseases is inhibited, and the effect of preventing and treating colitis and colitis-related colon cancer diseases is achieved. The nano-enzyme developed by the invention not only can relieve oxidative stress of diseases, but also can reduce the pro-inflammatory and tumor-promoting effects of cytokines, and can effectively treat colitis-related colon cancer caused by deterioration of colitis.

The invention belongs to the technical field of biological medicine, and discloses application of JAM3 protein in preparation of a medicine for inhibiting formation of a neutrophil extracellular trapping net. JAM3 is an I-type single transmembrane protein containing 310 amino acids, and belongs to an immunoglobulin superfamily. Researches show that the JAM3 protein remarkably inhibits excessive formation of a sepsis neutrophile granulocyte extracellular trapping net by regulating and controlling an activation path of neutrophile granulocytes, and meanwhile prevents blood platelets from being excessively captured, so that formation of microthrombus in the liver and damage to organs are avoided, disease progression is effectively controlled, and recovery of peripheral blood cells and organisms is promoted.

The application provides a high-purity human Orai2 membrane protein preparation method based on a mammalian cell expression system. The method obtains a recombinant expression vector containing a human Orai2 gene and an affinity tag sequence; the recombinant expression vector is transfected into a host cell line for expression; a membrane dissolving buffer containing dodecyl-beta-D-maltopyranoside and cholesteryl hemisuccinate is used for lysis extraction of the host cell; after centrifugation to obtain supernatant, the supernatant is sequentially separated and purified by using an affinity chromatography medium and a gel exclusion chromatography medium, and high-purity human Orai2 protein is obtained. The application constructs a thermodynamic equilibrium micellar microenvironment, solves the conformational inactivation problem in the extraction process of multiple transmembrane proteins, and realizes efficient and high-purity enrichment of human Orai2 protein.

Providing an adapter polypeptide and a method for using it. [Solution] Compositions of extracellular vesicles, as well as methods and systems for producing extracellular vesicles, are described herein. Methods for using extracellular vesicles are also described herein. This disclosure provides extracellular vesicles designed to target a wide variety of cell types, including different cells and organs in the body, as well as cells associated with disease or disorder. In some cases, the extracellular vesicles provided herein can be readily modified to bind specifically to a target. For example, they may include an extracellular domain that binds to a cell surface marker (e.g., the extracellular domain of a transmembrane protein within the membrane of the extracellular vesicle). Generally, the extracellular vesicles provided herein include an adapter polypeptide having an extracellular domain and, optionally, a transmembrane domain that binds to a cell surface marker.

The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and / or the cytokine-based T-cell activating transmembrane protein.

The invention provides an anti-SLC6A8 antibody or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, provided is an anti-SLC6A8 antibody or an antigen binding fragment thereof, which is capable of effectively binding to human SLC6A8 transmembrane protein. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment, and the antibody drug conjugate can be applied to preparation of drugs for treating overexpression SLC6A8 diseases, and has a good application prospect.

To provide methods for degrading target surface proteins in the ubiquitin pathway using bispecific binding agents or immunoconjugates that bind to the target surface proteins and membrane-bound ubiquitin E3 ligase.SOLUTION: The present invention relates, inter alia, to methods of degrading target surface proteins in the ubiquitin pathway using bispecific binding agents or immunoconjugates that bind to target surface proteins and membrane-bound ubiquitin E3 ligase. The present invention also relates to methods of degrading target surface proteins in the ubiquitin pathway using engineered membrane spanning proteins that bind to target surface proteins and exhibit ubiquitin E3 ligase activity. The present disclosure also provides compositions and methods useful for making bispecific binding agents and engineered transmembrane proteins, immunoconjugates, nucleic acids encoding them, host cells genetically modified with said nucleic acids, and methods of modulating the activity of cells and / or treating various diseases, such as cancer.SELECTED DRAWING: Figure 1

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

The present invention provides a central nervous system targeted pharmaceutical composition that can be used to treat various forms of brain damage, wherein an integrin antibody is attached to a transmembrane protein of an exosome through genetic engineering, and said exosome is used as a carrier to encapsulate a therapeutic drug.

The present disclosure provides novel protein isoforms, including transmembrane proteins, encoded by variant transcripts generated from non-canonical splicing, and corresponding peptides, nucleic acids, vaccines, antibodies and immune cells that can be used in diagnosis and therapy.

This invention discloses a preparation process for a targeted drug delivery system based on the synergistic effect of Lamp2b and IMTP, comprising the following steps: constructing cells overexpressing the Lamp2b-IMTP fusion protein, culturing cells overexpressing the Lamp2b-IMTP fusion protein, thereby obtaining the targeted drug delivery system. The Lamp2b / IMTP synergistic targeted drug delivery system obtained by this invention allows for the specific accumulation of drugs in target cells, such as tumor cells, achieving precise drug delivery. The fundamental localization role of Lamp2b: Lamp2b is a naturally occurring transmembrane protein on the surface of exosomes, responsible for mediating the "initial recognition" between exosomes and recipient cells, ensuring that the delivery system, with exosomes as the core carrier, can be effectively recognized and bound by cells, avoiding rapid clearance by the body as a "foreign substance."

A high-throughput screening for at least one ligand of at least one transmembrane protein (TP) of interest that is embedded in a lipid bilayer of at least one endogenous microsome derived from plant-based endoplasmatic reticulum (ER). The screening includes providing at least one endogenous microsome that includes at least one lipid bilayer embedded TP or at least one endogenous microsomal fragment that includes at least one lipid bilayer embedded TP, and providing at least one analyte of interest, contacting of the at least one TP with the at least one analyte and detection of interaction between the at least one analyte and the at least one TP. The screening is suitable for high multiplex grades of TPs and analytes and for a fast and reproducible identification of ligands as potential drug candidates. All essential products, consumables and kits for use in the high-throughput screening are described.

The invention relates to the technical field of biology, in particular to a kit based on functionalized magnetic beads and application of the kit in the field of stem cells. The surface of the functionalized magnetic bead is loaded with extracellular matrix protein, and the extracellular matrix protein is collagen. The functionalized magnetic bead provided by the invention realizes efficient capture and enrichment of collagen-bound transmembrane protein, and is suitable for screening stem cell transmembrane protein, researching action sites of stem cells and a matrix or developing drugs for targeting stem cells by combining mass spectrum identification. The kit and the method have the technical advantages of being easy and convenient to operate, good in stability and high in specificity, and a powerful tool is provided for systematically researching a stem cell transmembrane protein mediated cell-matrix interaction mechanism.

The invention discloses an application of a PRM1 gene in prevention and control of sugarcane smut, and the gene encodes a pheromone regulated multi-transmembrane protein which is a key factor for regulating sexual coordination and pathogenicity of pathogenic bacteria. Experiments show that inhibition or knockout of the PRM1 gene can significantly weaken the sexual cooperation ability of pathogenic bacteria, hinder the formation of binuclear hyphae and cause the reduction of the pathogenicity of the binuclear hyphae. In a molecular mechanism, PRM1 plays a role by influencing expression of a key gene of a pheromone signaling pathway. On the basis, the PRM1 gene and the encoding protein thereof are determined as a new target for preventing and treating the sugarcane smut, and can be used for developing novel green prevention and control technologies and products such as RNA interference preparations, specific inhibitors, gene editing breeding and engineering microorganisms, and a brand-new molecular basis and solution are provided for effectively controlling the sugarcane smut.

The present application relates to the field of biological medicine, and particularly relates to a kind of nanobody specifically binding transmembrane protein 132A and application thereof.The amino acid sequence of the nanobody is as shown in SEQ ID NO.23, SEQ ID NO.25 or SEQ ID NO.24.The present application first develops monoclonal nanobody targeting the mutual area of extracellular region of transmembrane protein 132A and extracellular region of EGFR, solves the bottleneck problem that although existing transmembrane protein 132A antibody targets its extracellular region, the targeted area is not located at the direct interaction interface of transmembrane protein 132A and EGFR, and cannot be used for functional study and targeted therapy, intervenes EGFR signal pathway from the angle of brand-new mechanism of action, can cover more extensive solid tumor patient population, and realizes broad-spectrum antitumor therapy.

The invention provides an anti-SLC6A8 antibody or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, provided is an anti-SLC6A8 antibody or an antigen binding fragment thereof, which is capable of effectively binding to human SLC6A8 transmembrane protein. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment, and the antibody drug conjugate can be applied to preparation of drugs for treating overexpression SLC6A8 diseases, and has a good application prospect.

The present application belongs to the field of microbial metabolic engineering, and particularly relates to a method for regulating human milk oligosaccharide production through transmembrane protein SgcC. The method is achieved by inactivating the transmembrane protein SgcC on a production strain. The present application obtains a human milk oligosaccharide production strain by gene editing technology to knockout or delete the 916th and 917th guanine bases of the transmembrane protein SgcC coding gene, and then inactivates the transmembrane protein SgcC. The human milk oligosaccharide production capacity of the strain is obviously improved compared with that before gene editing, wherein the LNT II yield is respectively increased by 19.4% and 25.8%; the LNnT yield is respectively increased by 50% and 75%; the LNT yield is respectively increased by 46.2% and 53.8%; the 3'-SL yield is respectively increased by 11.5% and 13.1%; and the 6'-SL yield is respectively increased by 19.4% and 22.6%. The effect is remarkable, and the present application provides a new method and idea for widening the human milk oligosaccharide production pathway.

The present invention belongs to the technical field of medicinal chemistry, and specifically relates to a targeted protein degradation complex containing an SYVN1 binding compound and the use thereof. The present invention identifies a series of compounds that interact with SYVN1. The compounds can be used as "warheads" to participate in ERAD and effectively degrade transmembrane protein targets. On the basis of the SYVN1 binding compound, a new TPD technology for hijacking ERAD is established, providing a brand-new platform for treating TMSPs and other proteins that are difficult to target by means of current TPD technologies. Further, the compounds that interact with SYVN1 are linked, via a chemical linker, to a known ligand that interacts with a protein target, thereby generating a series of ERADEC molecules. The molecules can significantly degrade the target protein, providing a new possibility for a targeted degradation drug.

In one aspect, the disclosure relates to 11C and 18F radiolabeled compounds useful as positron emission tomography (PET) tracers for selective imaging of neuroinflammation associated with expression transmembrane protein GPR84, methods of making the same, and compositions comprising the same. In one aspect, the compounds can cross the blood brain barrier, have a high signal to noise ratio, a large dynamic range, and are highly specific for their targets. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present application provides a central nervous system targeting pharmaceutical composition which can be used to treat various brain injury patterns, by genetically engineering an integrin antibody to bind to a transmembrane protein of an exosome, and coating the exosome as a carrier with a therapeutic drug.

The invention relates to fusion protein containing transmembrane protein and tetramer fluorescent protein and application of the fusion protein. Specifically, the present disclosure provides a fusion protein comprising a transmembrane protein and a tetramer fluorescent protein. The disclosure also provides extracellular vesicles comprising the fusion proteins, as well as uses of the fusion proteins or compositions or cells comprising the fusion proteins.